European Cohorts of Patients and Schools to Advance Response to Epidemics

Grant number: 101046016

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2021
    2026
  • Known Financial Commitments (USD)

    $11,595,267.2
  • Funder

    European Commission
  • Principal Investigator

    INCARDONA Francesca
  • Research Location

    Italy
  • Lead Research Institution

    EURESIST NETWORK GEIE
  • Research Priority Alignment

    N/A
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen genomics, mutations and adaptations

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Health PersonnelHospital personnel

Abstract

The EuCARE project gathers a comprehensive multidisciplinary team of clinicians, virologists, epidemiologists, statisticians and top experts in artificial intelligence to unveil the impact of SARS-CoV-2 variants on key sectors of public health, as addressed by the call. The specific activities include: 1. The assessment of natural and artificial immunity to the different viral variants in health care workers with the aim of defining the cross-immunization patterns and the risk of vaccine escape, informing vaccination strategies for the general population; 2. The analysis of the clinical course and long-term follow-up of hospitalized COVID-19 patients to derive the role of different viral variants in the outcome of the infection, including post-acute sequelae of SARS-CoV-2 infection; 3. The definition of the best strategies to control the spread of different viral variants in schools, by comparing the outcome of diverse containment and prevention measures in relation to the prevalence and dynamics of the variants. To ensure a suitable representativeness of the different variants, vaccines and preventive measures, EuCARE has secured the appropriate cohorts from diverse geographic areas including European countries, Kenya, Mexico, Russia and Vietnam, and will consolidate or expand interactions with other cohorts. To deal with complex interactions among many variables, including large dimensional parameters, EuCARE harnesses the power of artificial intelligence to define the role of viral variants and inform clinical guidelines and prevention measures. In the longer-term, EuCARE is committed to maintain active cooperation beyond the duration of the project with a dedicated task in the project. The solid IT and ethics infrastructure and the harmonised research procedures will make the cohort and laboratory network rapidly available to tackle newly emerging infectious diseases, thus contributing to pandemic preparedness on a global scale.

Publicationslinked via Europe PMC

Last Updated:43 minutes ago

View all publications at Europe PMC

Determinants of post COVID-19 clinic attendance among SARS-CoV-2-infected individuals in Stockholm, Sweden: a population-based cohort study.

Bacterial and Viral Coinfections in Adult Patients Hospitalized With COVID-19 Throughout the Pandemic: A Multinational Cohort Study in the EuCARE Project.

The Effect of COVID-19 Vaccination on the Risk of Persistent Post-COVID-19 Condition: Cohort Study.

Long-term immune responses to SARS-CoV-2 Omicron BA.4/5 mRNA booster in people living with HIV.

Impact of COVID-19 Pandemic on Delay of Melanoma Diagnosis: A Systematic Review and Meta-Analysis.

Oro-faecal transmission of SARS-CoV-2: A systematic review of studies employing viral culture from gastrointestinal and other potential oro-faecal sources and evidence for transmission to humans.

Outcomes of SARS-CoV-2 Omicron Variant Infections Compared With Seasonal Influenza and Respiratory Syncytial Virus Infections in Adults Attending the Emergency Department: A Multicenter Cohort Study.

Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild-Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir.

SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV.